Trial
NCT04535102
POLA+BR for Relapsed or Refractory DLBCL
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Colorado, Denver
Collaborators
National Cancer Institute (NCI)
Condition
Diffuse Large B Cell Lymphoma
Intervention
Polatuzumab Vedotin
Why stopped
Lack of sufficient patient population
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-09